ABRAXANE® Demonstrates Significant Improvement in Progression-Free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients

ABRAXANE® Demonstrates Significant Improvement in Progression-Free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients PR Newswire MELBOURNE, Australia, Oct. 25, 2012 - ABRAXANE shown to almost double progression free survival in phase III trial -- 4.8 months versus 2.5 months in comparator arm - Interim analysis of overall survival shows a positive trend for ABRAXANE -- 12.8 months compared to 10.7 months for comparator arm - Positive melanoma study supports ongoing development of ABRAXANE across multiple hard-to-treat tumor types; metastatic breast cancer, advanced non-small cell lung cancer and advanced pancreatic cancer MELBOURNE, Australia, Oct. 25, 2012 /PRNewswire/ -- Specialised Therapeutics Australia Pty Ltd today announced that abstracts for the upcoming Society for Melanoma Research meeting have been published online in the organization's official journal at http://onlinelibrary.wiley.com/doi/10.1111/pcmr.12023/abstract. The publication includes an abstract reviewing results from a phase III metastatic melanoma study with ABRAXANE® (nanoparticle albumin-bound paclitaxel). In the randomised, open-label, international study (CA033), ABRAXANE showed a statistically significant improvement in progression-free survival (PFS) in chemotherapy-naïve patients with metastatic melanoma compared to patients receiving dacarbazine chemotherapy (4.8 vs. 2.5 months, respectively (HR:0.792; 95.1% CI: 0.631, 0.992; P=0.044).